Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.

@article{Maillard2000PharmacologicPO,
  title={Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.},
  author={Marc Maillard and Julien Rossat and J{\"u}rg Nussberger and Joaqu{\'i}m Ramis and Carolina Nobre Ribeiro Pontes and Michel Burnier and Hans Rudolf Brunner},
  journal={Journal of cardiovascular pharmacology},
  year={2000},
  volume={35 3},
  pages={
          383-9
        }
}
This study was conducted to assess the pharmacologic properties of the new orally active angiotensin II subtype I (AT1) antagonist UR-7247, a product with a half-life >100 h in humans. The experiment was designed as an open-label, single-dose administration study with four parallel groups of four healthy men receiving increasing single oral doses (2.5, 5, and 10 mg) of UR-7247 or losartan, 100 mg. Angiotensin II receptor blockade was investigated < or =96 h after drug intake, with three… Expand
Clinical Pharmacology of Angiotensin II Receptor Antagonists
TLDR
Ten years after the introduction for clinical use of losartan, the first orally active angiotensin II receptor antagonist, seven compounds are registered by the US Food and Drug Administration and can be used in the United States and in various European countries for the treatment of hypertension, heart failure and for the prevention of type-2 diabetic nephropathy. Expand
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
TLDR
At their maximal recommended doses, neither LOS nor TEL blocks the RAS for 24 hours; hence, the addition of an ACE inhibitor provides an additional blockade. Expand
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
TLDR
The delayed in vivo blockade effect observed for enoltasosartan appears to be due to a high and tight protein binding and a slow dissociation process from the carrier, while the delayed in vitro blockade effect was markedly influenced by the presence of plasma proteins, leading to a decrease in its affinity for the receptor and a slower receptor association rate. Expand
Does protein binding modulate the effect of angiotensin II receptor antagonists?
TLDR
In vitro AT 1-antagonistic effects of different Ang II receptor antagonists were differentially affected by the presence of human plasma, with rightward shifts of the IC50 ranging from one to several orders of magnitude. Expand
In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor Antagonist
TLDR
When administered intravenously in rats, telmisartan is 10-fold more potent than irbesartan and comparable to candesartan, and ex vivo assessment of the AT1 receptor blockade using an in vitro AngII receptor binding assay shows similar results. Expand
Plasma protein binding: from discovery to development.
TLDR
The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clinically relevant, and provide drug metabolism and pharmacokinetics recommendations in discovery and development settings. Expand

References

SHOWING 1-8 OF 8 REFERENCES
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
TLDR
It is demonstrated that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects. Expand
Pharmacology of valsartan, an angiotensin II receptor antagonist.
TLDR
Three large clinical trials are now underway to demonstrate whether valsartan can reduce morbidity and mortality: one in hypertensives with a high cardiovascular risk profile (VALUE), one in patients with heart failure previously treated with an angiotensin-converting enzyme inhibitor (VAL-HeFT) and one in post-myocardial infarct patients (VALIANT). Expand
Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II
TLDR
DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men. Expand
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
TLDR
It is concluded that losartan produces a dose‐dependent, effective angiotensin II blockade that is largely determined by the active metabolite EXP3174. Expand
Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
TLDR
Compound 14n, a new series of 5-(biphenyl-4-ylmethyl)pyrazoles as potent angiotensin II antagonists, shows high potency both in vitro and in vivo and is selection for clinical evaluation as an antihypertensive agent. Expand
Angiotensin II measurement with high‐affinity monoclonal antibodies
Selectivity for the carboxy-terminus of angiotensin II (Ang II) and the high affinity of antibodies are prerequisites for clinical assays that evaluate Ang II in the presence of Ang I. AExpand
Actions of taurine on the L-type Ca2+ channel current in guinea pig ventricular cardiomyocytes.
TLDR
It is indicated that taurine modulates the open probability of L-type Ca2+ channel dependent on [Ca]i and [Ca[Ca]o, thereby maintaining the normal [ Ca]i level. Expand